FAQ

FAQ published on September 6, 2016
Join Dr. Robert Chen as he discusses new and emerging treatments in HL that are most likely to have the greatest impact on improving outcomes for relapsed or refractory disease.
FAQ published on August 4, 2016
Join Dr. Andrew Evens as he explains the relative roles of immunohistochemical studies versus flow cytometry results in the accurate diagnosis and assessment of patients with Hodgkin lymphoma.
FAQ published on July 7, 2016
Join Dr. Robert Chen as he discusses which treatment approaches may increase the potential for a higher cure rate in patients with relapsed or refractory Hodgkin lymphoma.
FAQ published on June 1, 2016
In this Managing Hodgkin Lymphoma FAQ, join Dr. Andrew Evens as he explains when it is appropriate and/or necessary to utilize mRNA testing in the diagnosis and staging of Hodgkin lymphoma (HL).
FAQ published on May 4, 2016
In this Managing Hodgkin Lymphoma FAQ, join Dr. Andrew Evens as he explains the top three factors that impact the development of treatment plans for newly diagnosed HL patients.
FAQ published on April 5, 2016
Join Dr. Robert Chen as he discusses the change in the treatment paradigm for patients with relapsed or refractory Hodgkin lymphoma in recent years.
FAQ published on March 3, 2016
Join Bruce D. Cheson, MD, in this Managing HL FAQ as he explains the alternatives that may be used to accurately stage Hodgkin lymphoma if a PET-CT is not available.
FAQ published on February 3, 2016
Join Bruce D. Cheson, MD, in this Managing HL FAQ as he explains whether or not CD30 is an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma.
FAQ published on January 11, 2016
Join Bruce D. Cheson, MD, in this Managing HL FAQ as he describes the strategies that can be utilized to accurately diagnose Hodgkin lymphoma in areas that lack adequate pathology.
FAQ published on August 12, 2015
Dr. Richard Hoppe explains the key issues in the NCCN Guidelines related to imaging patients with Hodgkin lymphoma.
Page 2 of 6
Results 11 - 20 of 56

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved